Reports Q3 revenue $39.97M, consensus $41.95M. “While PacBio (PACB) continued to operate in a difficult macro environment for capital purchases in the third quarter, we saw several positive signs that lead us to believe that we are on the path to return to growth in 2025 and beyond,” said Christian Henry, President and Chief Executive Officer. “We’re seeing sequential growth in consumables with growing sequencing data output, continued Revio adoption from new customers, and a record quarter for Onso. Meanwhile, we continue to decrease our cash burn and remain committed to our goal of being cashflow positive exiting 2026. Additionally, we’re strengthening our balance sheet by reducing our total debt while balancing dilution through our recently announced note exchange with SoftBank. With the launch of our SPRQ chemistry and the Vega benchtop system, PacBio is delivering on its strategy to bring a suite of advanced platforms and solutions to the market and expand HiFi’s ability to reach more customers than ever before.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Pacific Biosciences Faces Revenue Decline, Eyes Future Growth
- Pac Bio options imply 14.7% move in share price post-earnings
- Pacific Biosciences (PACB) Q3 Earnings Cheat Sheet
- PacBio announces SPRQ chemistry for Revio sequencing systems
- PacBio includes Onso platform in 10x Genomics Compatible Partner Program